[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564519":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":169,"collaborators":20,"id":171,"slug":20,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":20,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":20,"enrollmentInfo":179,"targetDuration":20,"studyType":182,"phases":183,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Deciphera Pharmaceuticals, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCC-3009 Module A","EXPERIMENTAL","Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation and Part 2 dose expansion.",[13],"Drug: DCC-3009",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","DCC-3009","Administered orally",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Clinical Team","STUDY_DIRECTOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","888-724-3274","clinicaltrials@deciphera.com",[31,42,53,68,83,97,111,125,140,154],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":20,"geoPoint":20,"contacts":38},"HonorHealth","RECRUITING","Scottsdate","Arizona","85258","United States",[39],{"name":40,"role":27,"phone":20,"phoneExt":20,"email":41},"Program Management","hriprograms@honorhealth.com",{"facility":43,"status":33,"city":44,"state":45,"zip":46,"country":37,"cosmosGeoPoint":47,"geoPoint":52,"contacts":20},"UC San Diego Moores Cancer Center","La Jolla","California","92093",{"type":48,"coordinates":49},"Point",[50,51],-117.2742,32.84727,{"lat":51,"lon":50},{"facility":54,"status":33,"city":55,"state":56,"zip":57,"country":37,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"University of Colorado Anschutz Medical Campus","Aurora","Colorado","80045",{"type":48,"coordinates":59},[60,61],-104.83192,39.72943,{"lat":61,"lon":60},[64],{"name":65,"role":27,"phone":66,"phoneExt":20,"email":67},"Steven Sares","303-724-9889","steven.sares@cuanschutz.edu",{"facility":69,"status":33,"city":70,"state":71,"zip":72,"country":37,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":48,"coordinates":74},[75,76],-81.65565,30.33218,{"lat":76,"lon":75},[79],{"name":80,"role":27,"phone":81,"phoneExt":20,"email":82},"Caroline Teeter","904-953-5141","teeter.caroline@mayo.edu",{"facility":84,"status":33,"city":85,"state":71,"zip":86,"country":37,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"University of Miami - Sylvester Comprehensive Cancer Center","Miami","33136",{"type":48,"coordinates":88},[89,90],-80.19366,25.77427,{"lat":90,"lon":89},[93],{"name":94,"role":27,"phone":95,"phoneExt":20,"email":96},"Leah Anton, ARNP","305-243-2529","lxa712@med.miami.edu",{"facility":98,"status":33,"city":99,"state":100,"zip":101,"country":37,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":48,"coordinates":103},[104,105],-71.05977,42.35843,{"lat":105,"lon":104},[108],{"name":109,"role":27,"phone":110,"phoneExt":20,"email":20},"Research Nurse","617-632-5204",{"facility":112,"status":33,"city":113,"state":114,"zip":115,"country":37,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"START Midwest","Grand Rapids","Michigan","49546",{"type":48,"coordinates":117},[118,119],-85.66809,42.96336,{"lat":119,"lon":118},[122],{"name":123,"role":27,"phone":20,"phoneExt":20,"email":124},"Hope Team","hopeteam@startresearch.com",{"facility":126,"status":33,"city":127,"state":128,"zip":129,"country":37,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":48,"coordinates":131},[132,133],-92.4699,44.02163,{"lat":133,"lon":132},[136],{"name":137,"role":27,"phone":138,"phoneExt":20,"email":139},"Jordan Meyers","507-284-2030","Meyers.jordan@mayo.edu",{"facility":141,"status":33,"city":142,"state":142,"zip":143,"country":37,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":48,"coordinates":145},[146,147],-74.00597,40.71427,{"lat":147,"lon":146},[150],{"name":151,"role":27,"phone":152,"phoneExt":20,"email":153},"Ping Chi, MD","646-888-4166","chip@mskcc.org",{"facility":155,"status":33,"city":156,"state":157,"zip":158,"country":37,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Vanderbilt University-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":48,"coordinates":160},[161,162],-86.78444,36.16589,{"lat":162,"lon":161},[165],{"name":166,"role":27,"phone":167,"phoneExt":20,"email":168},"Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)","800-811-8480","CTIP@VUMC.ORG",{"type":170,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100564519",false,"NCT06630234","A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","A Master Protocol for the Multi-cohort, Open-label, Phase 1\u002F2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)","Inclusion Criteria:\n\nModule A Part 1 (Escalation):\n\n* Any participant with histologically or cytologically confirmed advanced\u002Funresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced\u002Fmetastatic setting\n* Have at least 1 measurable lesion as defined by mRECIST, v1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n* Adequate organ function, bone marrow function, and electrolytes\n* All participants agree to comply with the contraception requirements\n* Have a life expectancy of more than 3 months\n\nExclusion Criteria:\n\n* Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug\n* Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer\n* Has known active central nervous system (CNS) metastases or an active primary CNS cancer\n* History or presence of clinically relevant cardiovascular abnormalities\n* Major surgery within 28 days of the first dose of study drug\n* Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n* Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug\n* Known allergy or hypersensitivity to any component of the study drug\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Any other clinically significant comorbidities","ALL","18 Years",{"count":180,"type":181},120,"ESTIMATED","INTERVENTIONAL",[184,185],"PHASE1","PHASE2","The purpose of this Phase 1\u002F2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.",[188],"Gastrointestinal Stromal Tumor (GIST)",[190,191],"PDGFRA mutations","KIT mutations","2026-02-03",{"date":194,"type":195},"2026-02-05","ACTUAL",{"date":197,"type":195},"2024-12-10",{"date":199,"type":181},"2028-05",{"name":5,"class":6},10]